SURYAMOL CHACKO: Open Payments
NPI 1053793927 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,038 in 22 payments from 15 companies in 2025. Trend: 2023 $2,487 · 2024 $1,680 · 2025 $2,038
Food & beverage: $2,038
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 2 | $247 |
| Phathom Pharmaceuticals, Inc. | 2 | $233 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $173 |
| Insmed, Inc. | 2 | $170 |
| VERTEX PHARMACEUTICALS INCORPORATED | 2 | $167 |
| Neurocrine BioSciences, Inc. | 1 | $140 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $125 |
| Madrigal Pharmaceuticals | 2 | $125 |
| Hologic Sales and Service, LLC | 1 | $119 |
| ABBVIE INC. | 1 | $111 |
Products named: VOQUEZNA, XIFAXAN, Arikayce, INGREZZA, NEFFY, REZDIFFRA, APTIMA, LINZESS.
Industry payments across MD — which companies pay providers there.
